GlassScriptPhysician profile
Michael Jakobsen
NPI 1730118118
$1,276.24
in general payments reported to CMS, 2019-2025
15 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.92 · 2021: $214 · 2022: $357 · 2023: $211 · 2024: $133 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $288.10 | 2021-2025 | Nucala |
| Optinose US, INC. | $235.52 | 2019-2024 | |
| Genzyme Corporation | $164.00 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $119.88 | 2022-2024 | Dupixent |
| Stryker Corporation | $96.36 | 2019-2021 | |
| Abbvie INC. | $75.33 | 2023-2025 | |
| Smith+Nephew, INC. | $72.65 | 2023-2025 | Tula, Halo, Rf20000 |
| Depuy Synthes Sales INC. | $38.44 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $36.87 | 2025 | Neffy |
| Biohaven Pharmaceutical Holding Company LTD. | $29.80 | 2022 | |
| Biocryst US Sales Co., LLC | $29.58 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $27.03 | 2025 | Tezspire |
| Aerin Medical INC. | $25.20 | 2024 | |
| Amgen INC. | $21.64 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $15.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jakobsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.